| Literature DB >> 32462950 |
Julia Ruiz-Vozmediano1, Sarah Löhnchen2, Lucas Jurado3, Rosario Recio4, Andrea Rodríguez-Carrillo2, Miriam López2, Vicente Mustieles2,5, Manuela Expósito4, Manuel Arroyo-Morales4, Mariana F Fernández2,4,5.
Abstract
Background: Integrative oncology has proven to be a useful approach to control cancer symptoms and improve the quality of life (QoL) and overall health of patients, delivering integrated patient care at both physical and emotional levels. The objective of this randomized trial was to evaluate the effects of a triple intervention program on the QoL and lifestyle of women with breast cancer.Entities:
Keywords: breast cancer; diet; exercise; integrative oncology; mindfulness; quality of life
Mesh:
Year: 2020 PMID: 32462950 PMCID: PMC7265566 DOI: 10.1177/1534735420924757
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.The CONSORT flow diagram.
Baseline Sociodemographic Characteristics of the Study Population.
| Variables | Control Group (n = 33) | Intervention Group (n =
34) | ||||
|---|---|---|---|---|---|---|
| Mean (SD) | P25 | P75 | Mean (SD) | P25 | P75 | |
| Age (years) | 48.33 ± 7.72 | 41 | 54 | 51.32 ± 10.15 | 44 | 59.25 |
| N | % | N | % | |||
| BMI (kg/m2) | ||||||
| Normal weight | 17 | 51.52 | 12 | 35.29 | ||
| Overweight | 7 | 21.21 | 10 | 29.41 | ||
| Obese | 9 | 27.27 | 12 | 35.29 | ||
| Residence | ||||||
| Urban | 20 | 60.61 | 19 | 55.88 | ||
| Rural | 13 | 39.39 | 15 | 44.12 | ||
| Education | ||||||
| Up to primary school | 15 | 45.45 | 16 | 47.06 | ||
| Secondary school | 7 | 21.21 | 6 | 17.65 | ||
| University degree | 11 | 33.33 | 12 | 35.29 | ||
| Income level | ||||||
| Low | 13 | 39.39 | 11 | 32.35 | ||
| Middle | 20 | 60.61 | 23 | 67.65 | ||
| Marital status | ||||||
| Single | 4 | 12.12 | 8 | 23.53 | ||
| With partner | 26 | 78.79 | 23 | 67.65 | ||
| Divorced/widowed | 3 | 9.09 | 3 | 8.82 | ||
| Employment/labor condition | ||||||
| Unemployed | 9 | 27.27 | 10 | 29.41 | ||
| Employed | 23 | 69.70 | 23 | 67.65 | ||
| Retired | 1 | 3.03 | 1 | 2.94 | ||
| Type of occupation | ||||||
| Sedentary | 10 | 30.30 | 7 | 20.59 | ||
| Standing | 17 | 51.52 | 12 | 35.29 | ||
| Physical work | 6 | 18.18 | 15 | 44.12 | ||
| Tobacco habit | ||||||
| Never smoked | 10 | 30.30 | 17 | 50.00 | ||
| Ex-smoker | 17 | 51.52 | 10 | 29.41 | ||
| Current smoker | 6 | 18.18 | 7 | 20.59 | ||
| Alcohol | ||||||
| No | 6 | 18.2 | 6 | 17.6 | ||
| Yes | 27 | 81.8 | 28 | 82.4 | ||
| Physical activity | ||||||
| No | 20 | 60.61 | 15 | 44.12 | ||
| Yes | 13 | 39.39 | 19 | 55.88 | ||
Abbreviations: SD, standard deviation; P, percentile; BMI, body mass index.
Baseline Dietary Characteristics of the Study Population.
| Control Group (n = 33) | Intervention Group (n =
34) | |||||
|---|---|---|---|---|---|---|
| Mean (SD) | P25 | P75 | Mean (SD) | P25 | P75 | |
| Total energy (kcal) | 1806.3 ± 626.8 | 1308.8 | 2161.8 | 1714.0 ± 533.6 | 1389.0 | 1976.1 |
| Carbohydrates (%) | 45.2 ± 11.3 | 38.2 | 49.4 | 46.8 ± 7.4 | 43.1 | 51.8 |
| Fat (%) | 38.6 ± 10.7 | 32.0 | 46.9 | 36.0 ± 5.8 | 31.9 | 39.0 |
| Proteins (%) | 15.4 ± 5.3 | 11.5 | 18.3 | 16.5 ± 4.2 | 13.5 | 19.0 |
| Dietary fiber (g) | 17.2 ± 6.0 | 13.7 | 21.5 | 20.0 ± 8.7 | 14.8 | 24.5 |
| Control Group (n = 33) | Intervention Group (n = 34[ | |||||
| N | % | n | % | |||
| Mediterranean diet[ | ||||||
| Low adherence | 23 | 69.7 | 19 | 55.9 | ||
| Good adherence | 10 | 30.3 | 14 | 41.2 | ||
Abbreviations: SD, standard deviation; P, percentile.
One questionnaire of Adherence to Mediterranean diet was not evaluated because of the participant’s complete lack of olfaction and taste after breast cancer treatment.
Low adherence (<9 points); good adherence (≥9 points).
Baseline Clinical Characteristics of the Study Population[a].
| Control Group (n = 33) | Intervention Group (n =
34) | |||
|---|---|---|---|---|
| N | % | n | % | |
| Family history of breast cancer | ||||
| No | 16[ | 50.00 | 23[ | 69.70 |
| Yes | 16[ | 50.00 | 10[ | 30.30 |
| Family history of other cancers | ||||
| No | 13 | 39.39 | 13 | 38.23 |
| Yes | 20 | 60.61 | 21 | 61.77 |
| ER | ||||
| Positive | 30[ | 93.75 | 26[ | 78.79 |
| Negative | 2[ | 6.25 | 7[ | 21.21 |
| HER2 | ||||
| Positive | 5[ | 15.63 | 7[ | 21.21 |
| Negative | 27[ | 84.37 | 26[ | 78.79 |
| Stage | ||||
| IIA | 13 | 39.39 | 19 | 55.88 |
| IIB | 19 | 57.57 | 13 | 38.23 |
| Unknown | 1 | 3.03 | 2 | 5.88 |
| Hormone therapy | ||||
| No | 5 | 15.15 | 4 | 11.76 |
| Yes | 28 | 84.85 | 30 | 88.24 |
Abbreviations: ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2.
In some groups, the sum of participants differs from the total number because information was missing from medical records.
No data for one woman.
Changes in Functional and Symptom Scales of QLQ-C30, Adherence to Mediterranean Diet, and Clinical Markers[a].
| Control Group (n =
32) | Intervention Group (n =
31) | |||||
|---|---|---|---|---|---|---|
| Baseline | End Follow-up[ |
| Baseline | End Follow-up[ |
| |
| Functional scales | ||||||
| Physical functioning | 80 (73.3-91.7) | 80 (61.7-93.3) | .992 | 73.3 (58.3-93.3) | 86.7 (73.3-93.3) | .001 |
| Role functioning | 91.7 (66.7-100) | 91.7 (33.3-100) | .071 | 83.3 (50-100) | 100 (83.3-100) | .05 |
| Cognitive functioning | 66.7 (37.5-100) | 66.7 (33.3-83.3) | .270 | 66.7 (45.8-83.3) | 83.3 (33.3-83.3) | .894 |
| Emotional functioning | 66.7 (33.3-91.7) | 75 (41.66-83.33) | .095 | 66.7 (47.9-85.4) | 75 (66.7-91.7) | .100 |
| Social functioning | 83.3 (50-100) | 91.66 (50-100) | .423 | 66.7 (45.8-100) | 100 (83.3-100) | .019 |
| Global health status | 62.5 (41.7-83.3) | 66.7 (43.7-83.3) | .662 | 62.5 (50-83.3) | 66.7 (66.7-83.3) | .589 |
| Symptom and problem scales | ||||||
| Fatigue | 22.2 (0-41.7) | 27.8 (2.8-63.9) | .053 | 33.3 (0-55.5) | 22.2 (11.1-44.4) | .693 |
| Pain | 33.3 (16.7-66.7) | 41.7 (20.8-66.7) | .471 | 33.3 (16.7-66.7) | 33.3 (0-66.7) | .759 |
| Dyspnea | 0 (0-33.3) | 16.7 (0-66.7) | .014 | 0 (0-33.3) | 0 (0-33.3) | .635 |
| Insomnia | 33.3 (8.3-66.7) | 66.7 (0-66.7) | .545 | 33.3 (0-66.7) | 33.3 (33.3-66.7) | .019 |
| Adherence to MD | ||||||
| MD score | 7.5 (6-9) | 8.0 (7-8) | .292 | 7.0 (6-10) | 10 (8-11) | .008 |
| Good adherence MD | ||||||
| n (%) | 10 (31%) | 7 (22%) | .375 | 14 (44%) | 24 (73%) | .035 |
| BMI (kg/m2) | 24.6 | 25.5 | .260 | 26.4 | 26.7 | .270 |
| Clinical markers | ||||||
| Total cholesterol (mg/dL) | 206 (181-121) | 188 (172-217) | 0.009 | 196 (169-245) | 181 (163.5-217) | .038 |
| LDL (mg/dL) | 134 (128-144) | 126 (116-141) | 0.049 | 161 (93-179) | 114 (91-152) | .01 |
| HDL (mg/dL) | 68 (57-73) | 59 (54-62) | 0.038 | 64 (48-72) | 57 (55-61) | .046 |
| Triglycerides (mg/dL) | 85 (72-102) | 111 (84- 135) | <0.001 | 102 (76-130) | 90 (76-110) | .077 |
| Ca 15.3 | 9.6 (7.4-12.9) | 12.3 (8.8-14.5) | 0.044 | 10 (9-14) | 10 (8-12) | 1 |
Abbreviations: QOL-30, quality of life test for oncology patients; MD, Mediterranean diet; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Ca 15.3, cancer antigen 15.3.
Variables are expressed as medians (IQR). p values for comparison of the mean change in variables among women inside the control or intervention groups between baseline and follow-up were obtained using the Mann-Whitney U test.
End follow-up: 6 months after intervention program.
CG Versus IG for Mean Change in Health Variables.
| CG, n = 32 | IG, n = 31 | IG Versus CG | |||||
|---|---|---|---|---|---|---|---|
| CG Baseline, Mean (SD) | CG 6 Months, Mean (SD) | Change, Mean (SD) | IG Baseline, Mean (SD) | IG 6 Months, Mean (SD) | Change, Mean (SD) |
| |
| Physical functioning | 79.2 (15.7) | 78.3 (18.9) | −0.89 (17.9) | 75.4 (19.5) | 85.0 (14.1) | 9.6 (14.4) |
|
| Social functioning | 73.4 (28.4) | 78.7 (28.5) | 5.2 (37.3) | 69.4 (29.8) | 83.3 (24.7) | 14.0 (32.8) | .429 |
| Role functioning | 81.3 (22.7) | 71.9 (32.1) | −9.4 (29.0) | 77.4 (25.3) | 86.6 (21.3) | 9.2 (28.5) |
|
| Cognitive functioning | 66.7 (33.3) | 58.9 (31.7) | 66.1 (29.7) | 66.1 (26.4) | 0.0 (24.0) | .330 | |
| Global health status | 62.2 (26.3) | 64.1 (22.7) | 1.82 (28.1) | 66.9 (23.2) | 69.4 (20.2) | 2.42 (18.2) | .928 |
| Fatigue | 26.4 (27.5) | 34.7 (32.3) | 8.3 (21.9) | 30.1 (28.6) | 28.3 (19.4) | .096 | |
| Pain | 39.6 (28.3) | 44.8 (30.7) | 5.2 (32.4) | 37.1 (29.1) | 35.5 (28.1) | .520 | |
| Dyspnea | 17.7 (26.8) | 31.3 (35.9) | 13.5 (29.2) | 17.2 (25.6) | 15.1 (25.6) |
|
|
| Insomnia | 48.0 (36.9) | 51.0 (36.9) | 3.1 (32.1) | 33.3 (32.2) | 48.4 (34.3) | 15.1 (32.0) | .102 |
| Emotional | 60.9 (29.2) | 66.7 (26.5) | 5.73 (24.9) | 66.4 (26.7) | 73.4 (24.9) | 6.99 (31.0) | .950 |
| MD score | 7.4 (2.2) | 7.8 (1.7) | 0.31 (1.73) | 8.1 (2.9) | 9.7 (1.7) | 1.57 (2.6) |
|
| High MD adherence n (%) | 10 (31.3) | 7 (21.9) | −9.4% | 13 (41.9) | 24 (77.4) |
|
|
| BMI (kg/m2) | 26.8 (6.0) | 27.0 (6.2) | 0.22 (1.05) | 28.0 (5.0) | 27.7 (4.9) |
|
|
| Weight (kg) | 68.9 (14.7) | 69.5 (15.0) | 0.55 (2.70) | 69.8 (12.0) | 69.0 (11.7) |
|
|
| Glucose (mg/dL) | 84.5 (10) | 86.9 (11.7) | 1.85 (9.4) | 83.2 (12.7) | 87.4 (14.1) | 4.2 (18.8) | .905 |
| TG (mg/dL) | 91.4 (31.7) | 111.9 (55.3) | 21.5 (32.3) | 106.8 (40.6) | 98.3 (36.8) |
|
|
| TC (mg/dL) | 204.9 (29.6) | 191.9 (30.3) | 209.4 (44.3) | 190.5 (34.8) | .670 | ||
| HDL (mg/dL) | 65.9 (8.5) | 59.3 (8.4) | −7.1 (8.4) | 61.2 (13.2) | 62.1 (14.1) | 0.92 (6.3) |
|
| LDL (mg/dL) | 133 (17.9) | 122 (26.9) | 195 (226) | 117.2 (31.5) | .113 | ||
| CA 15.3 (U/mL) | 13.0 (15.6) | 13.1 (14.9) | 11.5 (4.3) | 11.7 (4.9) | 0.55 (3.5) | .684 | |
Abbreviations: CG, control group; IG, intervention group; SD, standard deviation; MD, Mediterranean diet; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CA, cancer antigen.
Variables are expressed as means (SD).
Bold values shows the statistical significance.
p values for comparison of the mean change in health variables between control groups and intervention groups were obtained using Mann-Whitney U test.
p values obtained using Chi-squared test.